Eyepoint Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Eyepoint Inc 's ROA in the second quarter of 2026?
Eyepoint Inc recorded a cumulative net loss of $-307 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -83.88%.

However, within the Healthcare sector 753 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4218, from total ROA ranking in the first quarter of 2026 at 4819.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	8.71 %	-16.62 %	-8.85 %	3.03 %	11.19 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-307	-272	-232	-206	-175
Return On Assets (TTM)	-83.88 %	-75.84 %	-61.8 %	-53.26 %	-45.65 %
EYPT's Total Ranking	# 4218	# 4819	# 4143	# 4086	# 4039
Total Assets (TTM) in million	372	346	453	291	342
Seq. Total Assets Change	7.61 %	-23.74 %	55.53 %	-14.83 %	-17.46 %
Seq. Net Income Change	-	-	-	-	-

EYPT's 5 Years Annual ROA >> Back to EYPT Management Effectiveness >> Compare EYPT ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 24
Sector	# 754
Overall	# 4249

Return On Assets Statistics
High	Average	Low
40.11 %	-59.99 %	-144.55 %
(Sep 30 2014)		(Dec 31 2017)

News about Eyepoint Inc Return on Assets ROA

EyePoint Pharmaceuticals Initiates $100 Million Public Offering, Upsizes to $140 Million to Fuel Growth in Retinal Disease Treatments,

EyePoint Pharmaceuticals Expands Growth Horizon with Major Public Offering: Insights and ImplicationsOn October 28, 2024, EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pioneering company focused on innovative therapeutics for retinal diseases, announced its intention to initiate an underwritten public offering of common stock worth $100 million. This strategic move underscores both the company’s commitment to advancing ophthalmic therapies and its proactive approach to bolster its financial foundation amidst previously recorded losses. Strategic Offering OverviewIn the announced public offering, EyePoint plans to issue all shares on its own behalf, indicative of a self-reliant growth strategy. The offering also includes a 30-day option for underwriters to purchase an additional $15 million worth of common shares at the public offering price, minus underwriting discounts. Such provisions are typically designed to enhance liquidity and optimize the offerings based on market demand.

EyePoint Pharmaceuticals Grants Inducement Awards Amidst Financial Struggles

By

EyePoint Pharmaceuticals, a leading biopharmaceutical company specializing in the development and commercialization of therapies for serious retinal diseases, recently announced the grant of non-statutory stock options under NASDAQ Listing Rule 5635(c)(4) to new employees. This move comes as the company grapples with significant financial challenges, including a cumulative net loss of $100 million during the 12-month period ending in the third quarter of 2023, resulting in a negative return on assets (ROA) of -61.76%.
The decision to award inducement grants outside the Company s 2023 Long-Term Incentive Plan sheds light on EyePoint Pharmaceuticals strategic approach towards attracting and retaining top talent amidst its ongoing financial adversity. While inducement awards can play a crucial role in enhancing employee motivation and engagement, the company s financial struggles raise questions about this decision s long-term viability.

Financial Statements
Eyepoint Inc 's Assets	$ 372 million	EYPT's Balance sheet
Eyepoint Inc 's Income	$ -94 million	Quarterly EYPT's Income Statement
EYPT's Income by Division		See EYPT's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-8.85 %	35.6 %	21.59 %	-0.26 %	136.68 %
Total Assets in million	453	497	367	302	302
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-232	-131	-71	-102	-58
Annual Return On Assets	-51.18 %	-26.32 %	-19.31 %	-33.91 %	-19.32 %

EYPT's 5 Years Annual ROA >> Back to EYPT Management Effectiveness >> Compare EYPT ROA to its Competitors

More Return On Assets Ratios
EYPT's' Return on Assets at Yahoo Finance
Laboratory Analytical Instruments Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
EYPT's Roa Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for EYPT's Competitors
Subscribers only: Roa for Eyepoint Inc 's Suppliers
Subscribers only: Return On Assets for EYPT's Customers

You may also want to know
EYPT's Roi	EYPT's Inventory Turnover Ratio	EYPT's Growth Rates	EYPT's Dividend Comparisons
	EYPT's Profitability Ratios	EYPT's Asset Turnover Ratio	EYPT's Dividend Growth
EYPT's Roe	EYPT's Valuation Ratios	EYPT's Financial Strength Ratios	EYPT's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-10T13:21:22+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.